NCT00296803已完成4 期
PROCLAIM: Pilot Study Examining Effects of Clopidogrel Compared to Placebo on Markers of Inflammation in Subjects With Metabolic Syndrome
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 216
- 试验地点
- 2
- 主要终点
- To assess the effects of clopidogrel + aspirin vs placebo + aspirin on hs-CRP, CD40-ligand, soluble P-selectin, and other selected biomarkers in subjects with metabolic syndrome and elevated hs-CRP levels at study baseline
研究概览
简要总结
The purpose of this study is to examine the effects of clopidogrel compared to placebo on markers of inflammation in subjects with metabolic syndrome who are receiving background therapy including low dose aspirin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Men and women at least 18 years old
- •Women must be post-menopausal for one year, surgically sterilized, or using a medically accepted method of contraception and must agree to use an effective method of contraception throughout the study.
- •Subject must meet 3 of the 5 National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATP III) criteria for the classification of metabolic syndrome: triglycerides >/= 150 mg/dL; blood pressure (BP): systolic blood pressure (SBP) >/= 130 mmHg/diastolic blood pressure (DBP) > 85 mmHg; fasting glucose >/= 110 mg/dL; waist circumference: men - > 101.6 cm (40 in)/women - > 88.9 cm (35 in); high-density lipoprotein (HDL) cholesterol: men - < 40 mg/dL/women - < 50 mg/dL.
- •Subject has high-sensitivity C-reactive protein (hs-CRP) levels of >/= 2.0 but <10.0 mg/L at the Screening Visit (Week -2).
- •Current medication regimen must be stable for six (6) weeks, i.e. no initiation of new prescription medication nor change in dosage of any previously initiated medication within three months of entering this study.
- •Subject is normally active and judged to be in good health, based on medical history, routine safety laboratory tests (Screening Visit, Week -2), and a brief physical examination (Week -2).
排除标准
- •Intolerance or contraindication to the use of clopidogrel or aspirin.
- •Thrombocytopenia as defined by platelet count < 100,000/mm
- •Current use or use within the past 3 months of oral anticoagulants, or dipyridamole or thienopyridine (ticlopidine or open-label clopidogrel) or oral glucocorticoids.
- •Daily aspirin in excess of 81 mg, or chronic use of non-steroidal anti-inflammatory agents.
- •Use of oral hormone replacement therapy or oral contraceptives including transdermal patch.
- •History of pathologic bleeding (i.e., peptic ulcer or intracranial hemorrhage).
- •History of chronic inflammatory disease or any recent medical event(s) resulting in tissue injury, infection, or inflammation.
- •Myocardial infarction, coronary artery bypass graft, or angioplasty within the 6 months prior to Screening.
- •Uncontrolled hypertension (systolic blood pressure >/= 180 mmHg or diastolic blood pressure >/= 100 mmHg) at Screening.
- •History or presence of cancer in the past 2 years, except for successfully resected basal cell carcinoma of the skin.
- •Recent history (within the past 12 months) for alcohol or substance abuse.
- •Currently taking another investigational study medication or has taken investigational study medication within 30 days prior to Screening Visit.
- •Any condition the Investigator believes would interfere with evaluation of the subject, or which could put the subject at undue risk.
结局指标
主要结局
To assess the effects of clopidogrel + aspirin vs placebo + aspirin on hs-CRP, CD40-ligand, soluble P-selectin, and other selected biomarkers in subjects with metabolic syndrome and elevated hs-CRP levels at study baseline
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Pilot Study to Determine the Impact of Clopidogrel (Plavix®) on Bleeding Associated With Punch Biopsies in Healthy VolunteersHaemostasisHealthyNCT01603342Novo Nordisk A/S18
已完成
3 期
Clopidogrel in High-risk Patients With Acute Non-disabling Cerebrovascular EventsStrokeTransient Ischemic AttackNCT00979589Beijing Tiantan Hospital5,100
已完成
1 期
Interaction Study of Clopidogrel 300/75 mg Given Alone or With Omeprazole 80 mg 12 Hours Apart in Healthy SubjectsHealthyNCT01129388Sanofi72
已完成
1 期
Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy SubjectsHealthyNCT01129375Sanofi72
已完成
1 期
Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Pantoprazole 80 mg in Healthy SubjectsHealthyNCT01129427Sanofi66